In contrast, tumor angiogenesis in VEGFR2-Fc–expressing tumors was clearly inhibited by lenvatinib, although aflibercept and sorafenib appeared to slightly suppress tumor angiogenesis (Fig. 5f,g). The gene discussed is KDR; the disease is neoplasm.